Production (Stage)
Tango Therapeutics, Inc.
TNGX
$1.84
-$0.025-1.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.46% | -28.07% | -23.34% | -9.05% | -0.61% |
| Total Depreciation and Amortization | 1.50% | 3.48% | 5.41% | 14.50% | 30.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.39% | 45.23% | 19.12% | 31.04% | 28.98% |
| Change in Net Operating Assets | -5.50% | 16.38% | 38.46% | -43.95% | -51.92% |
| Cash from Operations | -11.91% | -11.46% | -2.98% | -11.94% | -5.78% |
| Capital Expenditure | 44.60% | 50.59% | 63.43% | 86.49% | 83.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56,723.79% | 102.27% | 2,656.65% | -128.37% | -100.30% |
| Cash from Investing | 9,732.98% | 107.90% | 1,449.99% | -131.88% | -101.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.27% | -42.33% | -40.59% | 9,621.40% | 8,674.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -96.26% | -42.16% | -40.88% | 9,602.85% | 8,657.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -189.39% | -60.87% | 85.26% | 60.76% | 107.07% |